Analysis of DOK-6 function in downstream signaling of RET in human neuroblastoma cells

Cancer Science

Volumn 101, Issue 5, 2010, Pages 1147-1155

  Kurotsuchi, Ai ^a   Murakumo, Yoshiki ^a   Jijiwa, Mayumi ^a   Kurokawa, Kei ^b   Itoh, Yasutomo ^a   Kodama, Yoshinori ^a   Kato, Takuya ^a   Enomoto, Atsushi ^a,c   Asai, Naoya ^a   Terasaki, Hiroko ^a   Takahashi, Masahide ^a  

^a NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AICHI MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c NAGOYA UNIVERSITY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

DOWNSTREAM OF KINASE 1; DOWNSTREAM OF KINASE 4; DOWNSTREAM OF KINASE 6; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; ONCOPROTEIN; PROTEIN RET; UNCLASSIFIED DRUG;

AMINO TERMINAL SEQUENCE; ARTICLE; BINDING AFFINITY; CELL MEMBRANE; CONTROLLED STUDY; GENE ACTIVATION; GENE INSERTION; GENE MUTATION; GENE SEQUENCE; HUMAN; HUMAN CELL; NERVE FIBER GROWTH; NEUROBLASTOMA CELL; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; SEQUENCE HOMOLOGY; SIGNAL TRANSDUCTION;

ADAPTOR PROTEINS, VESICULAR TRANSPORT; ANIMALS; CELL LINE, TUMOR; GLIAL CELL LINE-DERIVED NEUROTROPHIC FACTOR; HUMANS; MICE; NEUROBLASTOMA; PROTEIN STRUCTURE, TERTIARY; PROTO-ONCOGENE PROTEINS C-RET; SIGNAL TRANSDUCTION;

EID: 77953205964     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2010.01520.x     Document Type: Article

References (45)

1. Takahashi M, Buma Y, Iwamoto T, Inaguma Y, Ikeda H, Hiai H. Cloning and expression of the ret proto-oncogene encoding a tyrosine kinase with two potential transmembrane domains. Oncogene 1988, 3:571-8.
2. Pachnis V, Mankoo B, Costantini F. Expression of the c-ret proto-oncogene during mouse embryogenesis. Development 1993, 119:1005-17.
3. Avantaggiato V, Dathan NA, Grieco M. Developmental expression of the RET protooncogene. Cell Growth Differ 1994, 5:305-11.
4. Tsuzuki T, Takahashi M, Asai N, Iwashita T, Matsuyama M, Asai J. Spatial and temporal expression of the ret proto-oncogene product in embryonic, infant and adult rat tissues. Oncogene 1995, 10:191-8.
5. Airaksinen MS, Saarma M. The GDNF family: signaling, biological functions and therapeutic value. Nat Rev Neurosci 2002, 3:383-94.
6. Schuchardt A, D'Agati V, Larsson-Blomberg L, Costantini F, Pachnis V. Defects in the kidney and enteric nervous system of mice lacking the tyrosine kinase receptor Ret. Nature 1994, 367:380-3.
7. Durbec PL, Larsson-Blomberg LB, Schuchardt A, Costantini F, Pachnis V. Common origin and developmental dependence on c-ret of subsets of enteric and sympathetic neuroblasts. Development 1996, 122:349-58.
8. Takahashi M. The GDNF/RET signaling pathway and human diseases. Cytokine Growth Factor Rev 2001, 12:361-73.
9. Asai N, Jijiwa M, Enomoto A. RET receptor signaling: dysfunction in thyroid cancer and Hirschsprung's disease. Pathol Int 2006, 56:164-72.
10. Murakumo Y, Jijiwa M, Asai N, Ichihara M, Takahashi M. RET and neuroendocrine tumors. Pituitary 2006, 9:179-92.
11. Grieco M, Santoro M, Berlingieri MT. PTC is a novel rearranged form of the ret proto-oncogene and is frequently detected in vivo in human thyroid papillary carcinomas. Cell 1990, 60:557-63.
12. Mulligan LM, Kwok JB, Healey CS. Germ-line mutations of the RET proto-oncogene in multiple endocrine neoplasia type 2A. Nature 1993, 363:458-60.
13. Donis-Keller H, Dou S, Chi D. Mutations in the RET proto-oncogene are associated with MEN 2A and FMTC. Hum Mol Genet 1994, 2:851-6.
14. Carlson KM, Dou S, Chi D. Single missense mutation in the tyrosine kinase catalytic domain of the RET protooncogene is associated with multiple endocrine neoplasia type 2B. Proc Natl Acad Sci USA 1994, 91:1579-83.
15. Hofstra RM, Landsvater RM, Ceccherini I. A mutation in the RET proto-oncogene associated with multiple endocrine neoplasia type 2B and sporadic medullary thyroid carcinoma. Nature 1994, 367:375-6.
16. Romeo G, Ronchetto P, Luo Y. Point mutations affecting the tyrosine kinase domain of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:377-8.
17. Edery P, Lyonnet S, Mulligan LM. Mutations of the RET proto-oncogene in Hirschsprung's disease. Nature 1994, 367:378-80.
18. Carpino N, Wisniewski D, Strife A. p62(dok): a constitutively tyrosine-phosphorylated, GAP-associated protein in chronic myelogenous leukemia progenitor cells. Cell 1997, 88:197-204.
19. Yamanashi Y, Baltimore D. Identification of the Abl- and rasGAP-associated 62 kDa protein as a docking protein, Dok. Cell 1997, 88:205-11.
20. Di Cristofano A, Carpino N, Dunant N. Molecular cloning and characterization of p56dok-2 defines a new family of RasGAP-binding proteins. J Biol Chem 1998, 273:4827-30.
21. Cong F, Yuan B, Goff SP. Characterization of a novel member of the DOK family that binds and modulates Abl signaling. Mol Cell Biol 1999, 19:8314-25.
22. Grimm J, Sachs M, Britsch S. Novel p62dok family members, dok-4 and dok-5, are substrates of the c-Ret receptor tyrosine kinase and mediate neuronal differentiation. J Cell Biol 2001, 154:345-54.
23. Crowder RJ, Enomoto H, Yang M, Jonson EM, Millbrandt J. Dok-6, novel p62 Dok family member, promotes Ret-mediated neurite outgrowth. J Biol Chem 2004, 279:42072-81.
24. Okada K, Inoue A, Okada M. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 2006, 312:1802-5.
25. Beeson D, Higuchi O, Palace J. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 2006, 313:1975-8.
26. Noguchi T, Matozaki T, Inagaki K. Tyrosine phosphorylation of p62(Dok) induced by cell adhesion and insulin: possible role in cell migration. EMBO J 1999, 18:1748-60.
27. Murakami H, Yamamura Y, Shimono Y, Kawai K, Kurokawa K, Takahashi M. Role of Dok1 in cell signaling mediated by RET tyrosine kinase. J Biol Chem 2002, 277:32781-90.
28. Yamanashi Y, Tamura T, Kanamori T. Role of the rasGAP-associated docking protein p62(dok) in negative regulation of B cell receptor-mediated signaling. Genes Dev 2000, 14:11-6.
29. Bedirian A, Baldwin C, Abe J, Takano T, Lemay S. Pleckstrin homology and phosphotyrosine-binding domain-dependent membrane association and tyrosine phosphorylation of Dok-4, an inhibitory adapter molecule expressed in epithelial cells. J Biol Chem 2004, 279:19335-49.
30. Uchida M, Enomoto A, Fukuda T. Dok-4 regulates GDNF-dependent neurite out growth through down stream activation of Rap1 and mitogen-activated protein kinase. J Cell Sci 2006, 119:3067-77.
31. Hayashi H, Ichihara M, Iwashita T. Characterization of intracellular signals via tyrosine 1062 in RET activated by glial cell line-derived neurotrophic factor. Oncogene 2000, 19:4469-75.
32. Asai N, Murakami H, Iwashita T, Takahashi M. A mutation at tyrosine 1062 in MEN2A-Ret and MEN2B-Ret impairs their transforming activity and association with Shc adaptor proteins. J Biol Chem 1996, 271:17644-9.
33. Pierce B, Weng Z. ZRANK: reranking protein docking predictions with an optimized energy function. Proteins 2007, 67:1078-86.
34. Shi N, Ye S, Bartlam M. Structural basis for the specific recognition of RET by the Dok1 phosphotyrosine binding domain. J Biol Chem 2004, 279:4962-9.
35. Williger BT, Liscovitch M. Ras GTPase-activating protein-associated p62 is a major v-Src-SH3-binding protein. FEBS Lett 1997, 403:35-9.
36. Jones N, Dumont DJ. The Tek/Tie2 receptor signals through a novel Dok-related docking protein, Dok-R. Oncogene 1998, 17:1097-108.
37. Jones N, Dumont DJ. Recruitment of Dok-R to the EGF receptor through its PTB domain is required for attenuation of Erk MAP kinase activation. Curr Biol 1999, 9:1057-60.
38. Zhao M, Schmitz AA, Qin Y, Di Cristofano A, Pandolfi PP, Van Aelst L. Phosphoinositide 3-kinase-dependent membrane recruitment of p62(dok) is essential for its negative effect on mitogen-activated protein (MAP) kinase activation. J Exp Med 2001, 194:265-74.
39. Liang X, Wisniewski D, Strife A, Shivakrupa, Clarkson B, Resh MD. Phosphatidylinositol 3-kinase and Src family kinases are required for phosphorylation and membrane recruitment of Dok-1 in c-Kit signaling. J Biol Chem 2002, 277:13732-8.
40. Zhang Y, Yan Z, Farooq A. Molecular basis of distinct interactions between Dok1 PTB domain and tyrosine-phosphorylated EGF receptor. J Mol Biol 2004, 343:1147-55.
41. Lemay S, Davidson D, Latour S, Veillette A. Dok-3, a novel adapter molecule involved in the negative regulation of immunoreceptor signaling. Mol Cell Biol 2000, 20:2743-54.
42. Inoue A, Setoguchi K, Matsubara Y. Dok-7 activates the muscle receptor kinase MuSK and shapes synapse formation. Sci Signal 2009, 2:ra7.
43. Lemmon MA, Ferguson KM, Schlessinger J. PH domains: diverse sequences with a common fold recruit signaling molecules to the cell surface. Cell 1996, 85:621-4.
44. Forman-Kay JD, Pawson T. Diversity in protein recognition by PTB domains. Curr Opin Struct Biol 1999, 9:690-5.
45. Kurokawa K, Kawai K, Hashimoto M. Cell signalling and gene expression mediated by RET tyrosine kinase. J Intern Med 2003, 253:627-33.